Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics
LCTX Price/Volume Stats
| Current price | $1.10 | 52-week high | $1.61 |
| Prev. close | $1.14 | 52-week low | $0.84 |
| Day low | $1.10 | Volume | 747,300 |
| Day high | $1.15 | Avg. volume | 942,803 |
| 50-day MA | $1.22 | Dividend yield | N/A |
| 200-day MA | $1.20 | Market Cap | 207.39M |
LCTX Stock Price Chart Interactive Chart >
Lineage Cell Therapeutics, Inc. (LCTX) Company Bio
Lineage Cell Therapeutics, Inc. operates as a biotechnology company. The Company offers cell-based therapies and gene marker-based molecular diagnostics for diseases and degenerative conditions. Lineage Cell Therapeutics serves patients in the United States.
Latest LCTX News From Around the Web
Below are the latest news stories about LINEAGE CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate LCTX as an investment opportunity.
3 Penny Stocks to Buy for the Next Bull RunBy corporate protocol and just plain old common sense, when it comes to penny stocks to buy, your first instinct should be this: don’t. |
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript November 9, 2023 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.05. Operator: Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call […] |
Q3 2023 Lineage Cell Therapeutics Inc Earnings CallQ3 2023 Lineage Cell Therapeutics Inc Earnings Call |
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateCARLSBAD, Calif., November 09, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. |
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023CARLSBAD, Calif., November 01, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time/1:30 |
LCTX Price Returns
| 1-mo | -16.03% |
| 3-mo | 0.00% |
| 6-mo | -2.65% |
| 1-year | -18.52% |
| 3-year | -57.69% |
| 5-year | -10.57% |
| YTD | 0.92% |
| 2023 | -6.84% |
| 2022 | -52.24% |
| 2021 | 39.20% |
| 2020 | 97.75% |
| 2019 | -2.20% |
Loading social stream, please wait...